Topiramate (Eprontia) vs Topiramate (Topamax)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase · full Epilepsy pipeline

Topiramate (Eprontia)

Marketed by Azurity Pharmaceuticals

Approved in Epilepsysmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Topiramate (Topamax)

Marketed by Johnson & Johnson

Approved in Epilepsysmall molecule (anticonvulsant)
Partial signal

NCT00266591 · Phase 3 · completed

The study was randomized and double-blind with 51 participants, and its primary endpoint was the clinical measure of time to withdrawal for therapeutic failure. However, the comparator arm is not identifiable in the available record and no primary-outcome results were posted, so the trial provides limited interpretable evidence.

Reported efficacy

Video-recorded EEG was primary efficacy measure. Baseline vEEG and the vEEG at Visit 4 (Days 19 to 20; end point DB treatment phase or early withdrawal) will be read by a blinded central reader: Primary endpoint, median % reduction from baseline in daily partial-onset-seizure rate (video-EEG): topiramate 25 mg/kg 20.4% vs placebo 13.1% (p=0.97); 15 mg/kg dose p=0.97 vs placebo; 5 mg/kg dose p=0.91 vs placebo -- no dose significantly better than placebo. (missed)

Result source: NCT00113815

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointTopiramate (Eprontia)Topiramate (Topamax)
Seizure frequency, % change—Not reported—Not posted · NCT00266591
50% responder rate—Not reported—Not posted · NCT00266591
Seizure freedom—Not reported—Not posted · NCT00266591

Seizure frequency, % change

Topiramate (Eprontia)
—Not reported
Topiramate (Topamax)
—Not posted · NCT00266591

50% responder rate

Topiramate (Eprontia)
—Not reported
Topiramate (Topamax)
—Not posted · NCT00266591

Seizure freedom

Topiramate (Eprontia)
—Not reported
Topiramate (Topamax)
—Not posted · NCT00266591
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Topiramate (Eprontia): no structured comparison results are available for Epilepsy.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Topiramate (Eprontia): 0 of 4 rows · Topiramate (Topamax): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTopiramate (Topamax)
Dropout rate
34.3%Topiramate Monotherapya
NCT01627860 · Phase 4 · registry result, not featured evidence · monotherapy
show 5 more results
30%Topiramate add-on Therapy
NCT01627860 · Phase 4 · registry result, not featured evidence · combination
15.8%
NCT01689649 · Phase 4 · registry result, not featured evidence
—
NCT00855738 · Phase 4 · registry result, not featured evidence
18.8%Group A BIA 2-093 + Topamax
NCT02283814 · Phase 1 · registry result, not featured evidence · combination
12.5%Group B BIA 2-093 + Topamax
NCT02283814 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
25.7%Topiramate Monotherapya
NCT01627860 · Phase 4 · registry result, not featured evidence · monotherapy
show 5 more results
20%Topiramate add-on Therapy
NCT01627860 · Phase 4 · registry result, not featured evidence · combination
—
NCT01689649 · Phase 4 · registry result, not featured evidence
—
NCT00855738 · Phase 4 · registry result, not featured evidence
—Group A BIA 2-093 + Topamax
NCT02283814 · Phase 1 · registry result, not featured evidence · combination
—Group B BIA 2-093 + Topamax
NCT02283814 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
2.9%Topiramate Monotherapya
NCT01627860 · Phase 4 · registry result, not featured evidence · monotherapy
show 5 more results
5%Topiramate add-on Therapy
NCT01627860 · Phase 4 · registry result, not featured evidence · combination
0%
NCT01689649 · Phase 4 · registry result, not featured evidence
0%
NCT00855738 · Phase 4 · registry result, not featured evidence
0%Group A BIA 2-093 + Topamax
NCT02283814 · Phase 1 · registry result, not featured evidence · combination
0%Group B BIA 2-093 + Topamax
NCT02283814 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
a
dizziness 28.6%
hypoaesthesia 22.9%
headache 17.1%
NCT01627860 · Phase 4 · registry result, not featured evidence · monotherapy
show 5 more results
dizziness 20%
headache 15%
hyperhidrosis 10%
NCT01627860 · Phase 4 · registry result, not featured evidence · combination
weight loss 22.7%
anorexia 12.1%
fever 7.6%
NCT01689649 · Phase 4 · registry result, not featured evidence
somnolence 7.5%
weight increased 5%
dizziness 2.5%
NCT00855738 · Phase 4 · registry result, not featured evidence
somnolence 87.5%
paraesthesia oral 50%
headache 43.8%
NCT02283814 · Phase 1 · registry result, not featured evidence · combination
somnolence 81.3%
abdominal distension 43.8%
fatigue 37.5%
NCT02283814 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Topiramate (Topamax)

Seizure-free 88.57% (n=35) @ 16wk
responder rate · % of participants
Maintenance
No placebo or comparator arm
NCT01627860 · Phase 4 · registry result, not featured evidence · monotherapy
show 1 more result
65% (n=20) @ 16wk
NCT01627860 · Phase 4 · registry result, not featured evidence · combination
Seizure Frequency -55.3% (n=35) @ 16wk
percent change · % of baseline
No placebo or comparator arm
NCT01627860 · Phase 4 · registry result, not featured evidence · monotherapy
show 1 more result
-75.8% (n=20) @ 16wk
NCT01627860 · Phase 4 · registry result, not featured evidence · combination
Seizure 50 7% (n=139) @ 4.33wk
responder rate · % of participants
No placebo or comparator arm
NCT01689649 · Phase 4 · registry result, not featured evidence
show 2 more results
2.4% (n=139) @ 13wk
NCT01689649 · Phase 4 · registry result, not featured evidence
3% (n=139) @ 17.33wk
NCT01689649 · Phase 4 · registry result, not featured evidence
Seizure 75 20.3% (n=139) @ 4.33wk
responder rate · % of participants
No placebo or comparator arm
NCT01689649 · Phase 4 · registry result, not featured evidence
show 2 more results
16.9% (n=139) @ 13wk
NCT01689649 · Phase 4 · registry result, not featured evidence
16% (n=139) @ 17.33wk
NCT01689649 · Phase 4 · registry result, not featured evidence
Seizure-free 58.6% (n=139) @ 4.33wk
responder rate · % of participants
No placebo or comparator arm
NCT01689649 · Phase 4 · registry result, not featured evidence
show 2 more results
67% (n=139) @ 13wk
NCT01689649 · Phase 4 · registry result, not featured evidence
70% (n=139) @ 17.33wk
NCT01689649 · Phase 4 · registry result, not featured evidence

Migraine

Shared mechanism: Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase · full Migraine pipeline

Topiramate (Eprontia)

Marketed by Azurity Pharmaceuticals

Approved in Migrainesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Topiramate (Topamax)

Marketed by Johnson & Johnson

Approved in Migrainesmall molecule (anticonvulsant)
Partial signal

NCT00236509 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled, parallel-group trial in which 487 patients were randomized (480 planned) to three topiramate doses or placebo for 26 weeks. The primary endpoint, change in migraine frequency, is a clinical outcome; the 100 and 200 mg/day doses reduced it significantly versus placebo (p<0.001), but the 50 mg/day dose did not separate from placebo, so the primary comparison was only partly met and the grade is moderate. Figures are from the FDA label, which reports this study as Study 11.

Next expected readout: December 2027 · NCT05582837 (registry estimate)

Reported efficacy

Changes in length of time between the onset and cessation of painful migraine symptoms (migraine period) from the baseline. Safety evaluations conducted throughout the study.: Primary endpoint, change in mean 4-week migraine frequency (baseline to double-blind phase, ITT n=469): -1.3, -2.1 and -2.2 with topiramate 50, 100 and 200 mg/day vs -0.8 with placebo; 100 and 200 mg/day vs placebo p<0.001 (TOPAMAX label, Study 11 = TOPMAT-MIGR-001). (met)

Result source: NCT00236509

Results for Migraine

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Topiramate (Eprontia): no structured comparison results are available for Migraine.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Topiramate (Topamax)
Primary endpoint, change in mean 4-week migraine frequency (baseline to double-blind phase, ITT n=469): -1.3, -2.1 and -2.2 with topiramate 50, 100 and 200 mg/day vs -0.8 with placebo; 100 and 200 mg/day vs placebo p<0.001 (TOPAMAX label, Study 11 = TOPMAT-MIGR-001). NCT00236509 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Topiramate (Eprontia)'s landscape · Topiramate (Topamax)'s landscape